<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353765</url>
  </required_header>
  <id_info>
    <org_study_id>F-FR-60000-066</org_study_id>
    <nct_id>NCT04353765</nct_id>
  </id_info>
  <brief_title>Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors</brief_title>
  <acronym>US NIS Cabo</acronym>
  <official_title>Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate cabozantinib efficacy when administrated as treatment for metastatic Renal
      Cell Carcinoma (mRCC) after prior therapy with Check Point Inhibitors (CPIs)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6 months Response Rate</measure>
    <time_frame>From start of index treatment until 6 months of follow up or end of the treatment or death whichever occurs first</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>From start of index treatment until end of the treatment or death whichever occurs first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From start of index treatment until the earliest of death, end of study database, or evidence of Progressive Disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From start of index treatment until death or end of the study whichever occurs first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From date of index treatment response and the earliest date of progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>From start of index treatment until treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuation due to toxicity</measure>
    <time_frame>From start of index treatment until treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment dose reductions</measure>
    <time_frame>From start of index treatment until treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisations</measure>
    <time_frame>From start of index treatment until treatment discontinuation</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Locally Advanced or Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>cabozantinib arm</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib monotherapy</intervention_name>
    <description>Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).</description>
    <arm_group_label>cabozantinib arm</arm_group_label>
    <other_name>Cabometyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>All authorized TKI monotherapies in advanced RCC: sunitinib (Sutent), Pazopanib (Votrient), Axitinib (Inlyta); Lenvatinib (Lenvima) in combination with everolimus (Afinitor), sorafenib (Nexavar)</intervention_name>
    <description>As per authorized FDA label in advanced RCC</description>
    <arm_group_label>non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        USON network
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of metastatic Renal Cell Carcinoma (mRCC)

          -  Receipt of Check Point Inhibitors as the latest treatment for mRCC administrated
             before index treatment: Tyrosine Kinase Inhibitors

          -  Receipt of Tyrosine Kinase Inhibitors

          -  Patients who received care at a US Oncology Network site

        Exclusion Criteria:

          -  Age below 18 years old

          -  Patients enrolled in a clinical trial at any time during index treatment

          -  Patients receiving treatment for another documented primary cancer diagnoses during
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>McKesson Life Sciences</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

